非病毒纳米颗粒体内工程化 CAR 免疫细胞
In vivo engineering of CAR immune cells by nonviral nanoparticles.
92.1分
★★★★★
站内排序·非疗效
MODALITY HUB
FOR TREATMENT
现在就能报名的(招募中)排在最前,共 0 项。同一状态内中国中心优先。信息来自 ClinicalTrials.gov 与 CDE 公开登记。能否入组、费用与可及性,以登记原文和主治医生判断为准。
FOR RESEARCH
In vivo engineering of CAR immune cells by nonviral nanoparticles.
Chimeric antigen receptor-T cell therapy for T cell-derived hematological malignancies.
Allogeneic CD5-specific CAR-T therapy for relapsed/refractory T-ALL: a phase 1 trial.
T cells expressing CD5/CD7 bispecific chimeric antigen receptors with fully human heavy-chain-only domains mitigate tumor antigen escape.
Have CARs stalled for non-B-cell malignancies? Where are we, and where are we going?
MEMBER ACCOUNT
登录成功会直接打开下一页。